{"id":48770,"date":"2022-09-26T10:01:48","date_gmt":"2022-09-26T08:01:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/"},"modified":"2022-09-26T10:01:48","modified_gmt":"2022-09-26T08:01:48","slug":"tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/","title":{"rendered":"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer"},"content":{"rendered":"
\n

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA\u00ae<\/sup> (pembrolizumab), MSD\u2019s anti-PD-1 therapy.\n<\/p>\n

<\/a><\/p>\n

\nThis Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor refractory non-small cell lung cancer (NSCLC). This latest trial builds on the company\u2019s emerging data on the use of its oncolytic immunotherapy candidate TILT-123 currently in trials for several other indications where promising results of intravenous usability has motivated the expansion of the portfolio of trials.\n<\/p>\n

\nTILT Biotherapeutics\u2019 CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients, said, \u201cWe already have clinical trials running in Europe and the USA in several cancer types, including ovarian cancer, head and neck cancer, and melanoma. We are planning several more, one of which is this new collaboration in NSCLC with our collaborator MSD. Overall, our armed oncolytic viruses are showing potential in the clinic to increase the anti-tumor benefits of checkpoint inhibitors for a range of cancers where there is a pressing need for better therapies.\u201d\n<\/p>\n

\nThe heart of TILT\u2019s innovative approach revolves around the use of armed oncolytic adenoviruses, using cytokines and other molecules to boost the patient\u2019s T-cell immune response to better enable it to find and destroy cancer cells.\n<\/p>\n

\n-Ends-\n<\/p>\n

\nKEYTRUDA\u00ae<\/sup> is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.\n<\/p>\n

\nAbout TILT Biotherapeutics<\/b>\n<\/p>\n

\nTILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company\u2019s patented TILT\u00ae<\/sup> technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor infiltrating lymphocyte (TIL) therapy, and CAR T therapies.\n<\/p>\n

\nTILT\u2019s lead asset, TILT-123, is a 5\/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo<\/i>, and it is currently in Phase 1 clinical trials.\n<\/p>\n

\nThe Company\u2019s pioneering approach has been recognized by industry leaders including with the Merck KGaA and Pfizer Alliance, who are collaborating to investigate TILT-123\u2019s therapeutic effect in combination with the PD-L1 inhibitor, Avelumab (Bavencio\u00ae<\/sup>), in Head and Neck cancer (NCT05222932). The Company also has a collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, investigating TILT-123 in combination with pembrolizumab (KEYTRUDA\u00ae<\/sup>) in Ovarian Cancer (NCT05271318). In 2019, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of TILT\u2019s proprietary oncolytic virus TILT-123 in Greater China.\n<\/p>\n

\nBased in Helsinki, Finland, the company was established in 2013 as a spin-out from the University of Helsinki. It has funding from Lifeline Ventures, Finnish Industry Investment (TESI), angel investors, Business Finland, and the European Innovation Council (EIC).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTILT Biotherapeutics<\/b>
CBO Aino Kalervo
\n
aino@tiltbio.com<\/a><\/p>\n

Scius Communications<\/b>
Katja Stout
\n
+447789435990
\n
katja@sciuscommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA\u00ae (pembrolizumab), MSD\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48770","6":"format-standard","7":"category-industry"},"yoast_head":"\nTILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA\u00ae (pembrolizumab), MSD\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T08:01:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220926005002\/en\/1577374\/21\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer\",\"datePublished\":\"2022-09-26T08:01:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/\"},\"wordCount\":564,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220926005002\\\/en\\\/1577374\\\/21\\\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/\",\"name\":\"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220926005002\\\/en\\\/1577374\\\/21\\\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg\",\"datePublished\":\"2022-09-26T08:01:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220926005002\\\/en\\\/1577374\\\/21\\\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220926005002\\\/en\\\/1577374\\\/21\\\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer - Pharma Trend","og_description":"HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA\u00ae (pembrolizumab), MSD\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-26T08:01:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220926005002\/en\/1577374\/21\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer","datePublished":"2022-09-26T08:01:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/"},"wordCount":564,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220926005002\/en\/1577374\/21\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/","url":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/","name":"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220926005002\/en\/1577374\/21\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg","datePublished":"2022-09-26T08:01:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220926005002\/en\/1577374\/21\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220926005002\/en\/1577374\/21\/261e0c90-03ec-4979-b3cb-a988ed2e6333.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-clinical-trial-in-checkpoint-inhibitor-refractory-non-small-cell-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48770"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48770\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}